Vaccine maker Adimmune Corp (國光生技) yesterday said that it began the phase 1 trial of its COVID-19 vaccine this week.
The firm did not say when the first of an expected 70 participants was vaccinated and if there were any side effects.
It would reveal more information later, Adimmune said.
“Given that the novel coronavirus is mysterious, with some patients reportedly reinfected after being discharged, we would closely watch whether our candidate vaccine could induce an effective antibody against the virus and how long the antibody can remain protective,” Adimmune president Liu Chung-cheng (留忠正) told a media briefing in Taipei.
The company expects to enroll 70 volunteers by the middle of October with the help of National Taiwan University Hospital (NTUH), Liu said.
“Enrolling would take some time, as we are seeking volunteers who do not have chronic diseases, which is so determining a cause is not too difficult if side effects arise,” Adimmune spokesman Pan Fei (潘飛) said.
Adimmune, which previously planned to divide the 70 participants into three groups who would receive low, medium or high doses, would add one more group of participants to receive low doses combined with an adjuvant, which can boost the immune response of a vaccine, Pan said.
The plan is to apply to begin a phase 2 trial in early December, in which the candidate vaccine would be administered to 3,000 participants, Pan said.
The second-phase trial would include participants with other health issues to test the vaccine’s effect on such people, he said.
“Our goal is to enroll at least 1,500 participants for the phase 2 clinical trial, but the more the merrier,” Adimmune chairman Steve Chan (詹啟賢) said.
The company expects to end the phase 2 trial by Lunar New Year next year, which is in the middle of February, but it would continue monitoring participants for at least a year, Chan said.
As several companies and regulators in countries such as Brazil, Turkey, the Czech Republic, Singapore, Vietnam and the Philippines have expressed interest in cooperating with Adimmune on development of the vaccine, the firm would consider a multicenter, multinational phase 3 trial, Chan said.
Separately, TaiMed Biologics Inc (中裕新藥) on Tuesday signed a deal with Columbia University to gain access to a COVID-19 antibody developed by Aaron Diamond AIDS Research Center science director David Ho (何大一), a professor of medicine at the New York university who directed the work on the antibody, the firm said in a filing with the Taiwan Stock Exchange yesterday.
The antibody, among the nine that Ho’s team isolated from several patients severely infected with COVID-19, is expected to be a potent neutralizer of the novel coronavirus, TaiMed Biologics said.
The company would apply to the US Food and Drug Administration to conduct a phase 1 human test of the antibody in the spring of next year, TaiMed Biologics said.
It did not reveal the amount it paid to the university.
Dutch brewing company Heineken NV yesterday said that it has reached an agreement to acquire a subsidiary brewery of Taiwan’s Sanyo Whisbih Group (三洋維士比集團). Heineken is to assume majority ownership and management rights of the Long Chuan Zuan Co (龍泉鑽興業) brewery in Pingtung County’s Neipu Township (內埔), the Dutch company said. It would become the first multinational brewing company to operate brewery in Taiwan once the acquisition is completed. The deal has been approved by the Ministry of Economic Affairs’ Investment Commission, but details of the financial transaction cannot be disclosed at this time, as terms of the settlement have not been completed,
Had Audrey Hepburn and Gregory Peck hopped on an electric scooter rather than a Vespa in the classic film Roman Holiday, their spin around the Eternal City might have ended in tears. The number of crashes and near-misses involving the two-wheelers has prompted Rome authorities to impose some order on a booming rental market that began two years ago. The havoc came to a head earlier this month when two US tourists attempted a night-time drive down the Spanish Steps, causing more than 25,000 euros (US$26,392) worth of damage to the 18th-century monument. Caught on security footage, the couple in their late 20s
LOOK WHO OWES: China’s exposure to Taiwanese banks was the second-largest, with Luxembourg third, followed by Hong Kong and Japan, the central bank said The US remained the largest debtor country to Taiwan’s banking sector for a 27th consecutive quarter in the first quarter of this year, with its exposure rising 8.3 percent from a quarter earlier on the back of an increase in US bonds, the central bank said on Friday. Data compiled by the central bank showed that outstanding international claims by Taiwanese banks on a direct risk basis to the US stood at US$125.38 billion as of the end of March. Department of Financial Inspection deputy head Pan Ya-hui (潘雅慧) said that the US Federal Reserve’s launch of a rate hike cycle in
GREEN CITY: The company is set to invest US$8 billion to make electric vehicles and batteries for a new city that would rely entirely on renewable energy sources Indonesia said that Hon Hai Precision Industry Co (鴻海精密) is considering investing in the country’s new capital city, a move that would bolster the US$34 billion construction project. Hon Hai, which is known as Foxconn Technology Group (富士康科技集團), is looking at setting up an electric bus system and an Internet of Things network at Nusantara, as Indonesia’s new capital is to be called, Indonesian Minister of Investment Bahlil Lahadalia said in a statement yesterday. Hon Hai chairman Young Liu (劉揚偉) met with Indonesian President Joko Widodo on Saturday to discuss the company’s plan to invest US$8 billion to build a manufacturing plant
RSS